However, if an investor had purchased stock in the 30 components of the Dow in 1990 that were all deploying ERP, that investor would have benefited from a 35% decline in General and Administrative costs as a percentage of revenues, a five-fold increase in revenues as automation enabled massive scale, and an almost eight-fold increase in market cap.
But then you would downsize the scale of the clinical trial ten-fold, if you directed the drug mainly at patients most likely to respond to it based on the iPSC patient studies.